Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Celltrion Healthcare

- PMLiVE

Pfizer to acquire Seagen for $43bn in biggest pharma transaction since 2019

The deal includes four approved medicines and Seagen’s antibody-drug conjugate technology

Medscape Oncology: Delivering Impact at ASH

You can read more information on Medscape Oncology at ASH here, or please reach out to Chris Carey or Steve Dunn who can tell you more about how Medscape can help to...

Medscape Education Global

EU flag

European Commission grants AstraZeneca three new approvals

The indications are for adults with liver and lung cancers, and chronic lymphocytic leukaemia

EU flag

EC approves first gene therapy for adults with haemophilia B

Typically, haemophilia B patients must adhere to strict, lifelong IV infusion schedules

- PMLiVE

Ipsen to acquire worldwide rights to pre-clinical stage oncology programme

The company has an existing partnership with the Université de Montréal and IRICoR

EU flag

EC approves UCB’s Fintepla to treat severe form of epilepsy

Lennox-Gastaut syndrome affects around two in 10,000 people in the EU and usually begins in early childhood

- PMLiVE

ICR discovery could lead to new series of cancer drugs

The team found new inhibitors that block the action of a cancer-driving protein

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in EU

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis

This makes Dupixent the first and only targeted medicine indicated for this condition

- PMLiVE

Sandoz’s high concentration Hyrimoz formulation recommended for use in EU

The recommendation includes multiple indications such as rheumatoid arthritis and Crohn’s disease

- PMLiVE

Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients

Kate Shaw, Innovative Trials' Founder & CEM, reflects on the exciting news for patients affected by cancer in the UK.

Innovative Trials

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer

Breast cancer is one of the leading causes of cancer-related deaths globally, with more than two millions cases diagnosed in 2020

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links